Wave Life Sciences Ltd. Ordinary Shares

WVE

Wave Life Sciences Ltd. is a biotechnology company focused on the development of precision medicine therapies for genetic diseases. Founded with the goal of leveraging nucleic acid technologies, the company specializes in designing and developing synthetic oligonucleotide therapies to target specific genetic mutations, primarily in areas such as rare neurodegenerative and neuromuscular diseases. Headquartered in the United States, Wave Life Sciences aims to bring innovative treatments to patients with unmet medical needs through its proprietary platform.

$7.49 +5.36 (71.56%)
🚫 Wave Life Sciences Ltd. Ordinary Shares does not pay dividends

Company News

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire Inc. • Wave Life Sciences • November 5, 2025

Wave Life Sciences presented preclinical data for WVE-007, a novel RNA medicine targeting obesity by silencing INHBE mRNA. Preclinical studies showed potential for fat loss while preserving muscle mass, with promising initial clinical trial results demonstrating significant Activin E reduction.

Wave (WVE) Q2 Revenue Drops 56%
The Motley Fool • Na • July 31, 2025

Wave Life Sciences reported a challenging Q2 2025, with revenue declining 55.8% to $8.7 million and a net loss of $50.5 million. Despite financial setbacks, the company continues to advance its RNA-based medicine pipeline across multiple therapeutic areas.

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
Benzinga • Lekha Gupta • October 20, 2024

Several mid-cap stocks, including Oklo, CleanSpark, and Wolfspeed, saw significant gains last week. The article highlights the reasons behind the stock movements and encourages readers to check if these companies are in their portfolios.

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • April 30, 2024

NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Penny Stocks To Buy Now? 4 To Watch Before 2024
PennyStocks • J. Samuel • December 19, 2023

Are these penny stocks a buy before next year? The post Penny Stocks To Buy Now? 4 To Watch Before 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Related Companies